Aberrant METTL1-mediated tRNA m7G modification alters B-cell responses in systemic autoimmunity in humans and mice

  • Nat Commun. 2024 Dec 5;15(1):10599. doi: 10.1038/s41467-024-54941-4.
Shuyi Wang  #  1 ,  Hui Han  #  2 ,  Yichao Qian  1  3 ,  Xinyuan Ruan  1 ,  Zhangmei Lin  1 ,  Jin Li  1 ,  Binfeng Chen  1 ,  Yimei Lai  1 ,  Zhaoyu Wang  2 ,  Mengyuan Li  1 ,  Jingping Wen  1 ,  Xiaoyu Yin  4 ,  Niansheng Yang  1 ,  Shuibin Lin  2  3 ,  Hui Zhang  5  6
Affiliations
  • 1. Department of Rheumatology and Clinical Immunology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China.
  • 2. Center for Translational Medicine, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China.
  • 3. Institute of Precision Medicine, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China.
  • 4. Department of Pancreato-Biliary Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China.
  • 5. Department of Rheumatology and Clinical Immunology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China. [email protected].
  • 6. Institute of Precision Medicine, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China. [email protected].
  • # Contributed equally.
Abstract

Upon activation, naive B cells exit their quiescent state and enter germinal center (GC) responses, a transition accompanied by increased protein synthesis. How protein translation efficiency is adequately adjusted to meet the increased demand requires further investigation. Here, we identify the methyltransferase METTL1 as a translational checkpoint during GC responses. Conditional knockout of Mettl1 in mouse B cells blocks GC entry and impairs GC formation, whereas conditional knock-in of Mettl1 promotes GC responses. Mechanistically, METTL1 catalyzes m7G modification in a specific subset of tRNAs to preferentially translate BCR signaling-related proteins, ensuring mitochondrial electron transporter chain activity and sufficient bioenergetics in B cells. Pathologically, METTL1-mediated tRNA m7G modification controls B-cell autoreactivity in SLE patients or lupus-prone mice, and deletion of Mettl1 alleviates dysregulated B-cell responses during autoimmune induction. Thus, these results support the function of METTL1 in orchestrating an effective B-cell response and reveal that aberrant METTL1-mediated tRNA m7G modification promotes autoreactive B cells in systemic autoimmunity.

Products
Inhibitors & Agonists
Other Products